FDA announced that Novartis Pharmaceuticals has agreed to voluntarily discontinue marketing and sales of Zelnorm (tegaserod maleate). FDA's request was based on newly available information of an increased risk of serious heart adverse events, including heart attack, chest pain, and stroke. Based on this new information, FDA has concluded that the overall risk versus benefit profile for the drug is unfavorable for continued marketing.
